M Chadi Alraies, MD FACC

All Photos Twitter.com
Kicking off @TCTMD Conference with a bang! Strong team of our fellows @Cascadedesun @Irfan_shafis @TusharMishraMD @GoelMishita and residents @azizelkarim @RashidAlhusain attending and presenting this weekend. Mentorship from @chadialraies always much appreciated! #TCT2022
Retweeted by M Chadi Alraies, MD FACC
It was a pleasure to serve @crfheart @TCTMD and help spread the endless data and great silence twitter.com/shoaib9702/sta…
Thank you @TCTMD_Yael for the opportunity. Relevant and important topic for trainees as well as attendings. Got to know different perspectives. Would love to hear other point of views. @waynecardio @chadialraies #Cardiotwitter twitter.com/TCTMD_Yael/sta…
Retweeted by M Chadi Alraies, MD FACC
#SYMPLICITY HTN-3 trial shows significant ⬇️ in office & 24h ambulatory SBP to 3yrs w/ RDN compared w/ sham, independent of meds! Potential confounding factors may have played a role.. No late emerging complications.. #TCT2022 #LBCT @crfheart @TCTConference @DLBHATTMD #ACCIC
Retweeted by M Chadi Alraies, MD FACC
🙆🏽‍♂️PEMBERTON SIGN 😨Facial congestion 🥶cyanosis 😮‍💨respiratory distress —> SVC syndrome —>Think mediastinal ma#Cardiotwitterw#DVTr#VTET#cardiologyihNByhR
Retweeted by M Chadi Alraies, MD FACC
Great @crfheart #TCT2022 slide by @rwyeh re: 🔑 operator attributes for safe-effective “high-risk” and “complex” (not the same BTW) PCI: I’ve personally become both more “aggressive” yet also more “thoughtful” over time and act with more “confidence” yet also more “humility”👍GC
Retweeted by M Chadi Alraies, MD FACC
#TCT2022: two months outcomes of a randomized trial of renal denervation versus a sham procedure for uncontrolled moderate #hypertension. @panosxap reviews ✍️🏽 the RADIANCE II study 📊pcronline.com/News/Whats-new…Z6R
Retweeted by M Chadi Alraies, MD FACC
I’ve observed that many (if not all) live operators at #TCT2022 operate their own table for procedures. I trained this way and got away from it recently. Curious to know everyone’s practice. Do you pan for yourself in the cath lab? @fischman_david @DocSavageTJU @mmamas1973
Retweeted by M Chadi Alraies, MD FACC
We are very lucky to have you as a mentor @chadialraies . Thank you for the continuous support 🙌twitter.com/chadialraies/s…g
Retweeted by M Chadi Alraies, MD FACC
My @TCTMD interview with Stephen Fremes, surgical perspective of BCIS REVIVED ➡️ tctmd.com/videos/beyond-… ➡️Case selection for surgical revascularisation ➡️ Do we need a new surgical HF trial? @divaka_perera @ShelleyWood2 @DrPeterOKane @ncurzen @nolanjimradial @Hragy @LAzzaliniMD
Retweeted by M Chadi Alraies, MD FACC
Our #TCT2022 day 2 wrap up is live! @CMichaelGibson and @ajaykirtane discuss the renal denervation trials from today. Watch all the highlights here 🎥:tctmd.com/videos/tct-202…MV
Retweeted by M Chadi Alraies, MD FACC
Premiering at #TCT2022 is the new workflow for the how and what to assess #CMD. Created by a global group of experts. Thank you @nadia_sutton for presenting it today. And to @ziadalinyc amd @JEscaned for discussing it in the symposium this morning.
Retweeted by M Chadi Alraies, MD FACC
Excited to announce Penumbra’s next coronary clinical trial, CHEETAH-ACS, at #TCT2022 #CHEETAH #GetTheClotOut twitter.com/knshruthi/stat…
Retweeted by M Chadi Alraies, MD FACC
Super useful recommendations by master #CTO #PCI operator @CAThompson99 + great to sit on the panel with my mentor @MauroCarlino3 #TCT2022 @crfheart
Retweeted by M Chadi Alraies, MD FACC
We're honored to present the #TCT2022 Master Operator Award to Dr. Jean Fajadet. Join us at 10:45 AM ET to help celebrate his extraordinary contributions to #interventionalcardiology! ow.ly/i7S850KHxeI @PCRonline
Retweeted by M Chadi Alraies, MD FACC
Indirect ‘suggestion’ that #ultrasound-guided #femoral access alone doesn’t reduce minor/major #bleeding compared with fluoroscopy guidance. You also need #micropuncture kit. acc.org/Latest-in-Card…
Retweeted by M Chadi Alraies, MD FACC
RESCUE: In pts w/ intermediate-risk acute PE, pharmaco-mechanical catheter-directed thrombolysis with the Bashir Endovascular Catheter reduced RV/LV ratio by 33.3% and PA obstruction index by 35.9% at 48 hrs #TCT2022
Retweeted by M Chadi Alraies, MD FACC
PROTECTED TAVR: No Overall Stroke Reduction With Embolic Protection Devices in TAVR, But Fewer Disabling Strokes Summary and analysis, as well as more #TCT2022 coverage below: cardiologynownews.org/protected-tavr… @CMichaelGibson @leahkosyakovsky
Retweeted by M Chadi Alraies, MD FACC
CLASP II D RCT: In symptomatic degenerative mitral regurgitation, PASCAL valve repair system safe and non-inferior to MitraClip, resulted in low composite MACE thru 30 days and sustained improved MR thru 6 mo #TCT2022
Retweeted by M Chadi Alraies, MD FACC
HALT: In pts with self-expanding TAVs, no relationship btw duration of implant and thrombus / inflammation scores. Neointimal thickening, structural change, and calcification scores increased with time. #TCT2022
Retweeted by M Chadi Alraies, MD FACC
The PROTECTED TAVR trial showed that routine use of a CEP device does not result in a lower risk of #stroke within 72 hours among patients undergoing transfemoral #TAVR for #vhdAS. Find out more: bit.ly/3xvPsiL #TCT2022 @DLBHATTMD
Retweeted by M Chadi Alraies, MD FACC
Twiends™ uses the Twitter™ API, displays it's logo & trademarks, and is not endorsed or certified by them. These items remain the property of Twitter. We do not sell followers, we only provide display advertising. Bots & fake accounts are not permitted on twiends. © 2009
Grow Your Twitter Free
Want To Grow Your Twitter?
We help other people find and follow you on Twitter.
Key Info:
Started in 2009
Over 6 million signups
Country targeting provided
We never auto tweet to your timeline
We never auto follow others
We actively moderate our community
Please Share
Please upgrade your browser  chrome